Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI2 | P48307 | 4/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | SMURF2 | Q9HAU4 | 1/20 | 0.32 |
| ▸ | SMURF1 | Q9HCE7 | 1/20 | 0.32 |
| ▸ | KRAS | P01116 | 2/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
| ▸ | QDPR | P09417 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31549585 | 0.76 | KDM4E (0.35) | TFPI2NOTUMKDM4E | |
| SCHEMBL30988629 | 0.76 | CYP3A4 (0.38) | TFPI2NOTUMKDM4E | |
| SCHEMBL21625233 | 0.76 | CYP3A4 (0.38) | TFPI2NOTUMKDM4E | |
| SCHEMBL16401098 | 0.73 | KMT2A (0.40) | TFPI2KDM4E | |
| SCHEMBL29792740 | 0.73 | KMT2A (0.40) | TFPI2KDM4E | |
| SCHEMBL30988676 | 0.70 | THRA (0.35) | TFPI2KDM4E | |
| SCHEMBL4048895 | 0.69 | NOTUM (0.42) | NOTUMKDM4E | |
| SCHEMBL31668439 | 0.69 | L3MBTL1 (0.43) | KDM4E | |
| SCHEMBL16057016 | 0.69 | MEN1 (0.31) | KDM4E | |
| SCHEMBL30988642 | 0.69 | PPARD (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068951-A1 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2025-04-03 | — | — | WO | disclosed |